Introduction
Drug resistance in Mycobacterium tuberculosis (M. tuberculosis) has become a global problem in recent years and the emergence of multi drug resistant strains has dramatically increased the mortality worldwide. No tuberculosis-specific drug has been discovered for more than four decades. Mycobacterium bovis BCG (M. bovis BCG), an anti-TB vaccine, developed by Calmette and Guerin, has been used worldwide till date. But its protective efficacy against the pathogen varies from individual to individual. During infection, M. tuberculosis relies heavily on fatty acid metabolism for both energy supply and for synthesis of essential biomolecules required for its growth and survival in the living host [1] [2] [3] . Propionyl-CoA generated along with acetyl-CoA during the breakdown of odd-chain fatty acids and amino acids are reported to be potentially toxic to the mycobacteria [4, 5] . In mycobacteria, propionylCoA metabolism is linked to synthesis of essential lipid virulence factors like phthiocerol dimycocerosate (PDIM) and sulfolipid-1 (SL-1) [6] . M. tuberculosis metabolizes propionyl-CoA through methylcitrate cycle. Mycobacterial methylcitrate cycle consists of 2-methylcitrate synthase (Rv1131) and methylcitrate dehydratase (Rv1130) but do not contain a dedicated methylisocitrate lyase (MCL) [7, 8] .
Objective: To clone, express and purify 2-methylcitrate synthase (Rv1131) gene of Mycobacterium tuberculosis (M. tuberculosis) and to study its structural characteristics using various bioinformatics tools. Methods: Rv1131 gene was amplified by polymerase chain reaction using M. tuberculosis H37Rv genomic DNA and cloned into pGEM-T easy vector and sequenced. The gene was sub-cloned in pET28c vector, expressed in Escherichia coli BL21 (E. coli BL21) (DE3) cells and the recombinant protein was identified by Western blotting. The protein was purified using Nickel affinity chromatography and the structural characteristics like sub-cellular localization, presence of transmembrane helices and secondary structure of the protein were predicted by bioinformatics tools. Tertiary structure of the protein and phylogenetic analysis was also established by in silico analysis. Results: The expression of the recombinant protein (Rv1131) was confirmed by western blotting using anti-HIS antibodies and the protein was purified from the soluble fraction. In silico analysis showed that the protein contains no signal peptide and transmembrane helices. Active site prediction showed that the protein has histidine and aspartic acid residues at 242, 281 & 332 positions respectively. Phylogenetic analysis showed 100% homology with major mycobacterial species. Secondary structure predicts 2-methylcitrate synthase contain 51.9% alpha-helix, 8 .7% extended strand and 39.4% random coils. Tertiary structure of the protein was also established. Conclusions: The enzyme 2-methylcitrate synthase from M. tuberculosis H37Rv has been successfully expressed and purified. The purified protein will further be utilized to develop assay methods for screening new inhibitors.
Isocitrate lyase of glyoxylate pathway does MCL activity by its capability to accommodate both the substrates (methylisocitrate and isocitrate) in its active site [9] . 2-methylcitrate synthase catalyzes the condensation of propionyl-CoA with oxaloacetate to form 2-methylcitrate. Accumulation of 2-methylcitrate inside the cells is reported to inhibit the bacterial cell growth and blocks gluconeogenesis [10, 11] . Enzymes involved in methylcitrate cycle do not have homologue in humans and thus considered as potential target for new anti-tubercular drug development. To study the function of 2-methylcitrate synthase enzyme, we expressed the protein in Escherichia coli BL21 (E. coli BL21) (DE3) and purified using Ni-NTA affinity chromatography. Physical and structural characteristics of the purified protein were predicted using various bioinformatics tools. (India) . Standard recombinant DNA techniques used were as described elsewhere [17] .
Materials and methods
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PCR amplification of Rv1131
The nucleotide sequence of Rv1131 gene was retrieved from NCBI (http:// www.ncbi.nlm.nih.gov) for designing gene specific primers. PCR was performed using M. tuberculosis H37Rv genomic DNA as template (DMSO was added to the PCR reaction mixture to lower the melting temperature since M. tuberculosis H37Rv Genomic DNA is GC rich template). Rv1131 gene was amplified using gene-specific primers (Table 1 
Cloning of Rv1131 gene in E. coli
PCR products were gel purified and cloned into pGEM-T easy vector and sequenced. The plasmid containing Rv1131 gene was digested with BamH 栺 and Hind 栿, restriction enzymes and the digested gene product was gel purified and ligated into expression vector pET28c (digested with the same enzymes) overnight at 16 曟 . The ligated products were then transformed into E. coli DH5 毩 cells using standard protocol. Colonies were screened by PCR using T7 Promoter and T7 Terminator primers (Table 1 ) and the recombinant plasmid was isolated from the positive colonies by alkaline lysis method. The recombinant plasmid was then subjected to restriction analysis using BamH 栺 and Hind 栿 restriction enzymes.
Expression of Rv1131 gene in E. coli
The recombinant plasmid pET28c-Rv1131 was transformed into E. coli BL21 (DE3) cells for expression studies. A single colony of E. coli BL21 (DE3) containing pET28c-Rv1131 was inoculated in 5 mL of LB medium containing kanamycin (50 毺 g/mL) and grown at 37 曟 overnight. One mL of this culture was added in 100 mL fresh LB medium containing kanamycin (50 毺 g/mL) at 37 曟 until A 600 0.6 was reached. To the growing culture of E. coli BL21 (DE3) containing pET28c-Rv1131, IPTG was added to a final concentration of 1 mM and incubated at 30 曟 for 4 h. After induction, cells were harvested by centrifugation at 8 000 g for 10 min and the total proteins of the control and induced cells were analyzed by 12% SDS PAGE. The proteins were visualized by staining the gel with Coomasie blue (0.05%) for 30 min in a rocking shaker.
Purification and Western Blotting
E. coli BL21 (DE3) cells transformed with pET28c-Rv1131 were grown at 37 曟 in LB broth containing kanamycin (50 毺 g/mL) to an A 600 of 0.6 and the expression was induced by the addition of 1 mM IPTG for 4 h at 30 曟 . Cells from 500 mL culture were resuspended in 5 mL of buffer A (20 mM tris-HCL, pH 8.0, 500 mM NaCl, 30 mM imidazole, 1 mM PMSF and 10 毺 g/mL Lysozyme). After one cycle of freeze-thaw, cells were lysed by sonication (30 s pulse 暳 30 s pause). The soluble fraction was separated by centrifugation at 15 000 rpm for 30 min at 4 曟 and loaded on to a pre-equilibrated 2 mL (bed volume) Ni-NTA affinity column. After washing the column with 30 bed volumes of buffer B (50 mM tris-Cl, 500 mM NaCl, 40 mM imidazole, pH 8 .0) at a flow rate of 1.0 mL/min, the bound protein was eluted in buffer C (50 mM tris-Cl, 300 mM NaCl and 200 mM imidazole, pH 8.0). The purified proteins were quantified using Bradford method. For western blotting, the purified protein was electrophoresed on SDS-PAGE (12%) and transferred to PVDF membrane. After blocking, the membrane with Bovine serum albumin (5%) for 90 min, the membrane was probed with 1:5 000 dilution of anti-HIS mouse IgG antibody followed by HRP-conjugated goat anti-IgG antibody. The blot was developed using 3, 3'-Diaminobenzidine substrate. 
Results
Cloning of Rv1131 gene
Rv1131 gene was amplified by PCR ( Figure 1A) . A 1.2 kb DNA fragment containing an open reading frame of 393 amino acids was obtained. The gene was then cloned into pGEM-T easy vector and screened by blue/white screening method. The sequence of positive recombinant plasmid was verified by DNA sequencing. The positive recombinant plasmid was digested with BamH 栺 and Hind 栿 restriction enzymes and the gene product was gel purified and ligated with pET28c vector (digested with the same enzymes) and transformed into E. coli DH5 毩 . Colonies were screened by PCR using T7 promoter and T7 terminator primers (Table  1) to identify recombinant colonies. Recombinant plasmid was isolated from the positive colony and subjected to restriction analysis using BamH 栺 and Hind 栿, restriction enzymes ( Figure 1B ). The pET28c vector was chosen because it contains N-terminal 6 暳 His Tag which facilitates purification by Nickel affinity chromatography. 3 G250 and as expected a band at 43 kDa was observed (Figure 2A ). The solubility and cellular localization of the protein was analyzed by sonication of the cell pellet and subjecting the soluble and insoluble fractions to SDS-PAGE. 2-methylcitrate synthase was found to be present predominantly in the soluble fraction. Nickel affinity chromatography was used for purifying the protein from the soluble fraction.
Purification and identification of 2-methylcitrate synthase
The 2-methylcitrate synthase was purified from the soluble fraction. The supernatant soluble fraction was incubated with Ni-NTA agarose matrix overnight at 4 曟 and then loaded into the column. After washing the column with wash buffer, the bound proteins were eluted using elution buffer containing imidazole. The eluted fractions were then analyzed by SDS-PAGE. The analysis showed a single band at 43 kDa in the gel ( Figure 2B ). The eluted protein was confirmed by western blotting using anti-His IgG antibodies. The eluted fractions were subjected to SDS PAGE and transferred to PVDF membrane and probed using anti-His IgG antibodies. The blot was developed using 3,3'-diaminobenzidine and it showed a single band at 43 kDa ( Figure 2C ). (Figure 3 ). 2-methylcitrate synthase does not show the presence of signal peptide, transmembrane helices and was found to be located outside the membrane (Figure 4 ). An N-glycosylation site and an N-myristoylation site also have been predicted in the protein. Secondary 
Discussion
The genome of Mycobacteria consists of significant number of open reading frames (ORFs) that encode proteins that play a role in the growth or survival of the bacterium inside macrophages [7, 12] . Multidrug-resistant strains are on the rise, and its infection is often associated with HIV infection. Mycobacterial persistence inside the host macrophages remains the biggest challenge for developing new drugs against the pathogen. So far, the drugs which are available in the treatment of tuberculosis target only the actively growing bacteria. Metabolic adaptations are required for long term persistence of mycobacteria inside the host. M. tuberculosis shifts its energy source from glucose to fatty acids because it has the ability to induce formation of foamy macrophages which are loaded with large number of lipid-containing bodies [13] . Methylcitrate cycle, which enables M. tuberculosis to utilize fatty acids, has been identified as potential metabolic pathway that could be targeted by new drugs [14, 15] . Methylcitrate cycle is also known to be an important pathway for anaplerotic replenishment of tricarboxylic acid cycle intermediates and for gluconeogenesis in most of the cells [16] . In M. tuberculosis, it has been reported that tricarboxylic acid (TCA) intermediates are critical for infection [16] . The focus of this study is to identify potential new drug targets in M. tuberculosis. 2-methylcitrate synthase enzyme is one of the key enzymes of the most common propionyl-CoA metabolizing pathway in micro-organisms and is a conserved enzyme. Targeting this enzyme therefore could have multiple effects in M. tuberculosis: buildup of toxic propionyl CoA, inhibition of gluconeogenesis and on the overall efficiency of TCA because of its role in anaplerotic replenishment of the TCA intermediates.
Through bioinformatics tools its localization, modification sites and possible active sites residues have been identified which could enable researchers to develop new antituberculosis drugs by targeting 2-methylcitrate synthase enzyme.
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